Plain-English translation of NCT03933670 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new type of MRI scan that uses hyperpolarized carbon-13 pyruvate, an injectable tracer, to create detailed images of prostate cancer. The scan is designed to help doctors better understand which cancers are growing and which ones can be safely monitored without immediate treatment. Researchers want to see if this new imaging method can predict cancer behavior better than standard MRI scans.
Many men with low-risk prostate cancer are managed with active surveillance โ regular monitoring instead of immediate surgery or radiation. However, doctors currently have difficulty determining which cancers will remain slow-growing and which ones might become more aggressive. This trial aims to develop a better imaging tool to answer that question.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive an injection of the imaging tracer into your vein, which takes less than one minute. After 1โ2 minutes, you would undergo an MRI scan (which is like the standard MRI but records different information). You may be offered a second scan with the same tracer 15โ60 minutes later. Within 12 weeks after your baseline scan, you would also have a standard prostate biopsy guided by MRI and ultrasound so doctors can compare what the new scan shows with what they find on biopsy.
AI-generated summary from trial data ยท Jun 3, 2026 ยท Not medical advice
United States